BOSTON—Boston Micro Fabrication (BMF), a provider of advanced manufacturing technology for ultra-high precision applications, recently closed a landmark year in which it experienced a 30 percent growth in sales, the company said in a release.

Boston Micro Fabrication said it also secured its Series D funding, launched its technology in new markets, and expanded its San Diego Research Institute (SDRI), growing to more than 200 team members globally and serving more than 1,800 companies worldwide.

The company’s growth is grounded in its unique, high precision and micro resolution 3D printing technology, Projection Micro Stereolithography (PµSL). The technology leverages light, customizable optics, a high-quality movement platform, and controlled processing technology to produce what it called “the highest precision at the 2µm scale.”

Boston Micro Fabrication is focused on identifying unique applications for this technology using new materials such as BMF MED and Mechnano’s Formula1µ to help propel innovation across industries.

“Amid a challenging economic environment on both a global stage and for the 3D printing industry, we are very proud of the progress made over the last year to help our customers push the boundaries on what is possible with our technology,” said John Kawola, CEO of Boston Micro Fabrication, in the release. “ And while a lot of this success is due to strong execution from our team, much of it is based on our product-market focus and the fact that we are building a high value, differentiated business.”

In 2023, BMF entered the dental market with the launch of UltraThineer, the world’s thinnest cosmetic dental veneers. Cosmetic veneers are currently pressed or milled, and intrusive preparation and grinding are usually required to ensure a good fit. With UltraThineer, this grinding is minimized or eliminated, creating a better experience for patients with less time-intensive procedures for dentists, the company said.

The product is part of the company’s strategy to identify and develop high value applications where its technology platform can add unique value. Testing and development have been going well, BMF said, with clearance from the US Food and Drug Administration (FDA) expected by mid-2024.

“Small parts requiring very high levels of precision are difficult to prototype and manufacture, and we are continuing to address segments of the manufacturing and design market that may not be possible through other methods,” Kawola continued. “3D printing is a powerful tool here, and we’re continuing to uncover new applications for our technology.”

In 2023, BMF also began research at its San Diego Research Institute, a new research and development center in San Diego that has been formed specifically to develop and incubate end-product ideas that are uniquely enabled by BMF’s micro-3D manufacturing platform.

The first initiative underway is the development of next generation lab-on-chip structures that leverage the unique advantages of micro-3D printing for cell and tissue cultures. While the concept of a lab-on-a-chip was first introduced over 20 years ago, this new chip introduces a vascularized platform for drug discovery and cosmetic testing. The SDRI aims to revolutionize these industries through its ongoing research and development of new production methods and advanced capabilities for these structures, according to BMF.